ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

8,959Medicare Part D Prescriptions Filled, Including Refills

Rank: 149 out of 761

$524K Total Retail Price of All Prescriptions

Rank: 115 out of 761

601 Patients Receiving at Least One Drug in Part D
89%Patients 65 Years and Older
33% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Oregon
Lower avg

Schedule Two
Controlled Substances

6% of this provider’s 601 patients filled at least one prescription for a schedule two drug, compared to an average of 9%.

Schedule Three
Controlled Substances

11% of this provider’s 601 patients filled at least one prescription for a schedule three drug, compared to an average of 13%.

Risky Drugs to Seniors

1% of this provider’s 7,988 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

19% of this provider’s prescriptions were for brand-name drugs, compared to an average of 23%.

Prescription Price

$58 was the average price of a prescription from this provider, compared to $54 among peers.

Prescriptions per Patient

15 is the average number of prescriptions (including refills) per patient, compared to an average of 17.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Oregon
LISINOPRIL 376 353 1 1
OMEPRAZOLE 319 278 2 4
SIMVASTATIN 313 294 3 2
LEVOTHYROXINE SODIUM 305 280 4 3
ZOLPIDEM TARTRATE 295 271 5 22
CITALOPRAM HBR 270 252 6 19
PRAVASTATIN SODIUM 254 225 7 20
ALENDRONATE SODIUM 231 226 8 21
AMLODIPINE BESYLATE 212 201 9 6
HYDROCHLOROTHIAZIDE 205 187 10 11
METFORMIN HCL 193 165 11 10
LOVASTATIN 180 173 12 17
HYDROCODONE-ACETAMINOPHEN 177 139 S3 13 5
ATENOLOL 163 141 14 8
GABAPENTIN 151 133 15 15
LOSARTAN POTASSIUM 150 137 16 13
FUROSEMIDE 143 130 17 7
METOPROLOL TARTRATE 127 127 18 14
POTASSIUM CHLORIDE 125 106 19 18
ATORVASTATIN CALCIUM 112 108 20 12
TRAZODONE HCL 100 92 21 23
DONEPEZIL HCL 94 94 22 33
LISINOPRIL-HYDROCHLOROTHIAZIDE 93 82 23 35
CRESTOR 92 80 24 36
CARVEDILOL 90 83 25 26
ALLOPURINOL 89 87 26 28
METOPROLOL SUCCINATE 88 87 27 16
TAMSULOSIN HCL 85 80 28 27
FLUTICASONE PROPIONATE 79 71 29 29
RISPERIDONE 75 73 30 83
FENOFIBRATE 75 72 30 91
SERTRALINE HCL 74 56 32 25
FINASTERIDE 69 66 33 73
PANTOPRAZOLE SODIUM 67 49 34 40
NORTRIPTYLINE HCL 65 65 35 101
GLIMEPIRIDE 61 51 36 48
PREDNISONE 61 57 36 30
SPIRIVA 56 53 38 56
PROAIR HFA 55 36 39 32
ROPINIROLE HCL 53 53 40 95
CYMBALTA 53 25 40 53
LYRICA 52 33 42 134
DOXAZOSIN MESYLATE 52 52 42 55
NAMENDA 51 51 44 59
ADVAIR DISKUS 51 39 44 37
PAROXETINE HCL 50 27 46 47
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on April 11, 2013.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.